Kocis K C, Meliones J N, Dekeon M K, Callow L B, Lupinetti F M, Bove E L
Department of Pediatrics, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor 48109-0204.
Circulation. 1992 Nov;86(5 Suppl):II127-32.
Extracorporeal membrane oxygenation (ECMO) is considered when respiratory failure (RF) persists despite increasing conventional mechanical ventilation (CMV). High-frequency jet ventilation (HFJV) can improve ventilation with comparable mean airway pressure (PAW) to that found on CMV. This study was undertaken to determine whether HFJV is an effective treatment and alternative to ECMO for RF after congenital heart surgery.
HFJV was instituted in nine patients ranging in age from 6 days to 3.3 years with congenital heart disease meeting pulmonary criteria for ECMO. Indications for HFJV were pulmonary hypertension (six), adult-type respiratory distress syndrome (two), and pneumonitis (one). Seven patients (77%) were placed on HFJV within 24 hours of operation, and two patients required HFJV 2 weeks after operation. HFJV resulted in resolution of RF in eight of nine patients (89%). After 1 hour of HFJV, the arterial pH increased from 7.40 +/- 0.1 to 7.56 +/- 0.1 (p < 0.05) and the PaCO2 decreased from 44 +/- 15 to 29 +/- 12 mm Hg (p < 0.05). During HFJV there was no change in PaO2, although the FIO2 decreased from 0.99 +/- 0.0 to 0.73 +/- 0.2 (p < 0.05). There was no change in PAW, peak inspiratory pressures, positive end-expiratory pressures, heart rate, or mean arterial blood pressure during HFJV when compared with CMV. Mean duration of HFJV was 43 hours. Four patients were extubated and discharged from the hospital. Two patients were extubated but died from sepsis. Two patients had resolution of RF, but one died at reoperation and one from multisystem organ failure. The patient who failed HFJV therapy was placed on ECMO and died.
This study suggests that HFJV improves ventilation and is an alternative to ECMO in patients with RF after surgery for congenital heart disease.
尽管常规机械通气(CMV)不断增加,但呼吸衰竭(RF)持续存在时,可考虑使用体外膜肺氧合(ECMO)。高频喷射通气(HFJV)能在与CMV相当的平均气道压(PAW)下改善通气。本研究旨在确定HFJV对于先天性心脏病手术后RF是否为一种有效的治疗方法及ECMO的替代方案。
对9例年龄从6天至3.3岁、患有先天性心脏病且符合ECMO肺部标准的患者实施HFJV治疗。HFJV的适应证为肺动脉高压(6例)、成人型呼吸窘迫综合征(2例)及肺炎(1例)。7例患者(77%)在术后24小时内接受HFJV治疗,2例患者在术后2周需要HFJV治疗。HFJV使9例患者中的8例(89%)呼吸衰竭得到缓解。HFJV治疗1小时后,动脉血pH从7.40±0.1升至7.56±0.1(p<0.05),动脉血二氧化碳分压(PaCO₂)从44±15降至29±12 mmHg(p<0.05)。HFJV期间动脉血氧分压(PaO₂)无变化,尽管吸入氧分数(FIO₂)从0.99±0.0降至0.73±0.2(p<0.05)。与CMV相比HFJV期间PAW、吸气峰压、呼气末正压、心率或平均动脉血压均无变化。HFJV的平均持续时间为43小时。4例患者拔管并出院。2例患者拔管但死于败血症。2例患者呼吸衰竭缓解,但1例在再次手术时死亡,1例死于多系统器官衰竭。HFJV治疗失败的患者接受ECMO治疗后死亡。
本研究提示HFJV可改善通气,是先天性心脏病手术后呼吸衰竭患者ECMO的替代方案。